We are live on ! Find out more
RPAM

Rhenman & Partners Asset Management Portfolio holdings

AUM $810M
1-Year Est. Return 30.2%
This Fund
S&P 500
This Quarter Est. Return
+5.87%
1 Year Est. Return
+30.2%
3 Year Est. Return
+116.38%
5 Year Est. Return
+153.13%
10 Year Est. Return
+962.25%
AUM
$833M
AUM Growth
+$240M
Cap. Flow
+$158M
Cap. Flow %
18.98%
Top 10 Hldgs %
35.14%
Holding
103
New
14
Increased
42
Reduced
34
Closed
7

Top Buys

Rank Stock Value
1
JNJ icon
Johnson & Johnson
JNJ
+$19.1M
2
UNH icon
UnitedHealth
UNH
+$11.9M
3
COO icon
Cooper Companies
COO
+$7.39M
4
ESRX
Express Scripts Holding Company
ESRX
+$6.9M
5
MDT icon
Medtronic
MDT
+$6.56M

Top Sells

Rank Stock Value
1
AMGN icon
Amgen
AMGN
+$4.81M
2
OCR
OMNICARE INC
OCR
+$3.85M
3
GILD icon
Gilead Sciences
GILD
+$3.17M
4
LGND icon
Ligand Pharmaceuticals
LGND
+$3.01M
5
MCK icon
McKesson
MCK
+$3.01M

Sector Composition

Rank Sector Weight
1 Healthcare 76.95%
2 Financials 0.78%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RVNC
51
DELISTED
Revance Therapeutics, Inc.
RVNC
$5.5M 0.66%
172,000
-64,000
-27% -$1.65M
TEVA icon
52
Teva Pharmaceuticals
TEVA
$41.2B
$5.44M 0.65%
92,000
+42,000
+84% +$2.59M
IONS icon
53
Ionis Pharmaceuticals
IONS
$9.4B
$5.41M 0.65%
94,000
-8,000
-8% -$509K
ANTH
54
DELISTED
Anthera Pharmaceuticals, Inc.
ANTH
$5.34M 0.64%
77,450
-10,214
-12% -$473K
CLVS
55
DELISTED
Clovis Oncology, Inc.
CLVS
$5.34M 0.64%
60,765
+6,765
+13% +$579K
KERX
56
DELISTED
Keryx Biopharmaceuticals Inc
KERX
$5.33M 0.64%
534,000
+237,000
+80% +$2.54M
RCPT
57
DELISTED
RECEPTOS INC COM STK (DE)
RCPT
$5.32M 0.64%
28,000
-15,500
-36% -$2.56M
MDVN
58
DELISTED
MEDIVATION, INC.
MDVN
$5.25M 0.63%
92,000
-46,000
-33% -$2.84M
IOVA icon
59
Iovance Biotherapeutics
IOVA
$2.87B
$5.1M 0.61%
+556,000
New +$6.21M
TTPH
60
DELISTED
Tetraphase Pharmaceuticals, Inc.
TTPH
$5.09M 0.61%
5,370
-730
-12% -$597K
CLDX icon
61
Celldex Therapeutics
CLDX
$3.28B
$4.97M 0.6%
13,133
+5,200
+66% +$2.07M
THOR
62
DELISTED
THORATEC CORPORATION
THOR
$4.9M 0.59%
110,000
+23,000
+26% +$1.01M
AMSG
63
DELISTED
Amsurg Corp
AMSG
$4.9M 0.59%
70,000
-6,000
-8% -$401K
TMO icon
64
Thermo Fisher Scientific
TMO
$220B
$4.8M 0.58%
+37,000
New +$4.82M
ENDP
65
DELISTED
Endo International plc
ENDP
$4.7M 0.56%
58,976
+32,235
+121% +$2.78M
COR icon
66
Cencora
COR
$61.2B
$4.47M 0.54%
42,000
+4,000
+11% +$451K
CNC icon
67
Centene
CNC
$32.5B
$4.34M 0.52%
108,000
+12,000
+13% +$431K
XNCR icon
68
Xencor
XNCR
$1.55B
$4.13M 0.5%
188,000
-2,000
-1% -$34.1K
MGNX icon
69
MacroGenics
MGNX
$257M
$4.1M 0.49%
107,959
+1,959
+2% +$64.4K
KITE
70
DELISTED
Kite Pharma, Inc.
KITE
$4.02M 0.48%
66,000
+21,000
+47% +$1.2M
EW icon
71
Edwards Lifesciences
EW
$51.7B
$3.99M 0.48%
168,000
+54,000
+47% +$1.22M
OREX
72
DELISTED
Orexigen Therapeutics, Inc.
OREX
$3.91M 0.47%
78,900
-4,280
-5% -$256K
HALO icon
73
Halozyme
HALO
$12.2B
$3.88M 0.47%
+172,000
New +$3.02M
ZLTQ
74
DELISTED
ZELTIQ Aesthetics, Inc.
ZLTQ
$3.8M 0.46%
+129,000
New +$3.89M
ARIA
75
DELISTED
Ariad Pharmaceuticals Inc
ARIA
$3.72M 0.45%
450,000
+63,000
+16% +$557K
1 2
3
4 5

Similar funds

PS
Portfolio Strategies Monsey, New York $811M AUM 28.91% 1-Year Est. Return
ACM
Ashford Capital Management Wilmington, Delaware $809M AUM 35.1% 1-Year Est. Return
AR
Advisory Research Chicago, Illinois $813M AUM 36.71% 1-Year Est. Return
KCP
Kera Capital Partners San Jose, California $815M AUM 46.39% 1-Year Est. Return
BCM
Brigade Capital Management New York $806M AUM 20.71% 1-Year Est. Return
RIM
Redwood Investment Management Scottsdale, Arizona $805M AUM 15.01% 1-Year Est. Return
GCM
Glendon Capital Management Santa Monica, California $805M AUM 17.91% 1-Year Est. Return
CL
CVFG LLC Shelbyville, Indiana $804M AUM 27.61% 1-Year Est. Return

Rhenman & Partners Asset Management's Q2 2015 Portfolio in Review

As of Q2 2015, Rhenman & Partners Asset Management held 103 positions worth $833M, up 40% from $593M the previous quarter. Its ten largest holdings account for 35% of the portfolio.

Rhenman & Partners Asset Management deployed $158M of net new capital in Q2 2015, opening 14 new positions and adding to 42 existing holdings. Its largest new stake was Johnson & Johnson: 191,000 shares worth $18.6M.

By sector, the portfolio is most concentrated in Healthcare at 77% of assets, down from 84% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was Amgen, an estimated $4.81M trimmed.

  • Rhenman & Partners Asset Management's largest Q2 2015 buy was Johnson & Johnson: 191,000 shares worth $18.6M.
  • Rhenman & Partners Asset Management added most to UnitedHealth in Q2 2015, an estimated $11.9M increase.
  • Rhenman & Partners Asset Management's biggest Q2 2015 reduction was Amgen, cutting an estimated $4.81M.
  • Rhenman & Partners Asset Management fully exited OMNICARE INC in Q2 2015, selling an estimated $3.85M.
  • Rhenman & Partners Asset Management's ten largest holdings make up 35% of its $833M portfolio in Q2 2015.
  • Rhenman & Partners Asset Management opened 14 new positions and closed 7 in Q2 2015.
  • Rhenman & Partners Asset Management's portfolio value rose 40% quarter-over-quarter to $833M.

Based on Rhenman & Partners Asset Management's 13F filing for Q2 2015, filed 30 Jul 2015.